Stay updated on Cabozantinib Reverses Carfilzomib Resistance in Myeloma Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib Reverses Carfilzomib Resistance in Myeloma Clinical Trial page.

Latest updates to the Cabozantinib Reverses Carfilzomib Resistance in Myeloma Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check19 days agoChange DetectedA unified Locations section now lists Nebraska and Texas as study sites. The separate Nebraska Locations and Texas Locations sections were removed, the HHS Vulnerability Disclosure link was removed, and the page revision advanced to v3.3.3.SummaryDifference0.3%

- Check26 days agoNo Change Detected
- Check40 days agoChange DetectedRevision updated to v3.3.2 (replacing v3.3.1). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check47 days agoChange DetectedPage revision updated from v3.2.0 to v3.3.1. No study content or data appears to be changed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check55 days agoChange DetectedThe notice regarding a lapse in government funding and potential data updates has been removed from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check69 days agoChange DetectedNo significant changes detected in core content; only cosmetic formatting changes were observed on the Study Details page, and there are no updates to inclusion criteria, primary outcomes, or enrollment. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check98 days agoChange DetectedThe page now includes an operating-status notice and a version update to v3.2.0, while removing the previous v3.1.0 reference.SummaryDifference2%

Stay in the know with updates to Cabozantinib Reverses Carfilzomib Resistance in Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib Reverses Carfilzomib Resistance in Myeloma Clinical Trial page.